Skip to content
  • EnglishEnglish
  • SvenskaSvenska
 

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

  • About us
    • Management
    • Board of Directors
  • Diseases
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Mangoral
    • Clinical Development Mangoral
    • Oncoral
    • Clinical Development Oncoral
    • Oncoral Phase 2 Plans
  • IR & Media
    • Press releases & News
    • Reports & Presentations
    • Share
    • Shareholders
    • Equity research
    • Subscribe to press releases
    • Ascelia Pharma in Media
    • IPO (completed 2019)
    • IR Contact
    • Financial calendar
    • CMD 2020
    • Events
  • Corporate governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Open applications
    • Our values
    • Meet us
  • Contact

Reports & Presentations

  • All
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Regulatory
2020-11-05 | Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch
Download
Presentation
Webcast
Excel
Regulatory
2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study
Download
Presentation
Webcast
Excel
Regulatory
2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE
Download
Presentation
Webcast
Excel
Regulatory
2020-04-06 | Ascelia Pharma publishes Annual Report for the financial year 2019
Download
Presentation
Webcast
Excel
Regulatory
2020-02-14 | 2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE
Download
Presentation
Webcast
Excel
Regulatory
2019-11-08 | Q1 2019/2020 Financial Report: Preparations for Phase III study with Mangoral® on track
Download
Presentation
Webcast
Excel
Regulatory
2019-10-14 | Ascelia Pharma publishes Annual Report for the financial year 2018/2019
Download
Presentation
Webcast
Excel
Regulatory
2019-08-22 | Full-year financial report 2018/2019: Phase III study of Mangoral to start in H2-2019
Download
Presentation
Webcast
Excel
Regulatory
2019-05-15 | Q3 2018/2019 Financial Report (Jan-Mar 2019): Fully financed Phase III program for Mangoral through the IPO
Download
Presentation
Webcast
Excel

  • Ascelia Pharma AB

  • Hyllie Boulevard 34

  • 215 32 MALMÖ

  • Sweden

  • +46 735 179 118

Ascelia Pharma © 2019 | All Rights Reserved

Privacy policy Ascelia Pharma AB

We use cookies. Read more about cookies or read our Privacy Policy

Close
Video